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Background: Type 2 diabetes is a complex metabolic disorder characterized by hyperglycemia, impaired glucose
tolerance and insulin resistance associated with dyslipidemia and hypertension. The available drugs are not sufficiently
efficacious in reducing cardiovascular risk and restoring normal glucose metabolism associated with type 2 diabetes
as a mono- or a combination therapy. The present study examined the combined effects of an antihypertensive
(S-Amlodipine) and an insulin-sensitizing agent, peroxisome proliferator-activated receptor (PPAR) agonists
(Pioglitazone and Ragaglitazar), on cardiovascular risk factors in aged diabetic and insulin-resistant Zucker fa/fa rats.
Methods: Following combination treatment for 14 days, blood pressure (BP), serum glucose, total cholesterol and
triglycerides were measured. Aortic ring study was conducted to determine the effect of combination treatments on
phenylephrine-induced vasoconstriction and acetylcholine (Ach)-induced vasorelaxation.
Results: In combination, S-Amlodipine and Pioglitazone significantly reduced blood glucose (115.1 ± 6.6 vs. 81.7 ± 4.2),
BP (184.4 ± 5.0 vs. 155.1 ± 5.0), serum triglycerides (362.5 ± 47.5 vs. 211.1 ± 23.7) and glucose intolerance when
compared with vehicle treated Zucker fa/fa rats. Similar results were observed with the combination of S-Amlodipine
and Ragaglitazar (Triglycerides, 362.5 ± 47.5 vs. 252.34 ± 27.86; BP, 184.4 ± 5.0 vs. 159.0 ± 8.0) except for serum glucose.
ACh-induced vasorelaxation in aortic rings was also superior with both of the combinations compared to individual
treatment. Furthermore, there was less body weight gain and food intake with S-Amlodipine and Pioglitazone
combination in Zucker fa/fa rats. S-Amlodipine itself caused significant reduction in glucose (115.1 ± 6.6 vs. 89.7 ± 2.7) and
BP (184.4 ± 5.0 vs. 156.1 ± 4.0) with improvement in insulin sensitivity observed through oral glucose tolerance test.
Conclusions: The results suggest that a combination of PPAR agonists and S-Amlodipine has partial benefits in
improving the cardiovascular risk factors such as reduction in triglyceride levels, associated with chronic type 2
diabetes, and therefore may be utilized as an approach for addressing some of these devastating metabolic
syndrome complications.
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Diabetes mellitus [1] is characterized by hyperglycemia
resulting from defects in insulin secretion, insulin action
or both. Type 2 DM is the most common form of diabetes
[2]. According to the World Health Organization, up to 3
billion people will be affected with DM by the year 2025.
Type 2 DM is a heterogeneous, progressive disorder ini-
tially characterized by impaired glucose tolerance and
compensatory hyperinsulinemia, which in the later stages,
develops severe insulin resistance and impaired beta cell
function [2,3]. This is associated with hyperglycemia,
dyslipidemia, hypertension, obesity and in the long
term, micro-and macro-vascular complications leading
to increased mortality [4]. Hypertension (blood pressure
[BP] ≥140/90 mmHg) is an extremely common condi-
tion in diabetes, affecting around 20 to 60% of diabetic
patients [5]. Unfortunately, none of the available drugs
for clinical use have proved sufficiently efficacious in re-
ducing cardiovascular risk and restoring normal glucose
metabolism in mono or in combination therapy as the
disease progresses [6].
Peroxisome proliferator-activated receptors (PPARs) are
transcription factors belonging to the superfamily of nu-
clear receptors. Three isoforms (alpha, beta and gamma)
have been identified [7]. PPAR-gamma agonists, also
known as thiazolidinediones (TZDs), such as Pioglita-
zone and Rosiglitazone increase insulin sensitivity, re-
duce levels of blood glucose, insulin and triglycerides
with a concomitant reduction in BP and improvement
in endothelial function [8,9]. PPAR-alpha agonists in the
form of fibrates have been in use for the treatment of
dyslipidemia [10]. PPAR-alpha and PPAR-gamma were
empirically discovered owing to their ability to improve
insulin sensitivity and lipidemia, respectively in rodents
[11,12]. Endothelium dependent relaxation is impaired
in diabetic conditions [13]. Zucker fa/fa rats are insulin
resistant, hyperglycemic and have blunted endothelium
vasorelaxation [14]. In addition, a considerable number
of in-vitro and in-vivo studies reported impact of TZDs
on the cardiovascular system including reduction in BP,
restoration of blunted endothelium-mediated vasodila-
tion, attenuation of sympathetic overactivity, inhibition
of intracellular Ca2+ increase, and proliferation of vas-
cular smooth muscle cells [13,15-17]. Consequently, ag-
onists with dual PPAR-alpha and gamma activity would
potentially have beneficial effects superior to those ob-
tained with drugs activating either of the PPAR subtypes
alone. Ragaglitazar, a non-TZD compound has a com-
bined PPAR-alpha/gamma agonist activity both in-vitro
and in-vivo and reported efficacious in lowering blood
glucose and lipid profile [4].
Calcium channel blockers (CCBs) are one of the most
widely used drugs for the treatment of hypertension asso-
ciated with type 2 DM [18]. Some preliminary previousstudies have demonstrated reduced levels of blood glucose
and lipid parameters in different rat models as well as in
humans with CCBs, but results were not significant
[19,20]. The impact of combination treatment of CCB and
PPAR agonist in Zucker fa/fa rats remains unknown.
The present study was conducted to evaluate the im-
pact of combination treatments of CCB and PPAR ago-
nist (S-Amlodipine + Pioglitazone and S-Amlodipine +
Ragaglitazar) on biochemical and cardiovascular parame-
ters in aged Zucker fa/fa rats.Materials and methods
Materials
Ragaglitazar and Pioglitazone were synthesized and
obtained from the chemistry department, Zydus Re-
search Center, Ahmedabad, India. Phenylephrine (PE),
L-NAME and Ach were obtained from Sigma (USA).
All other reagents were of analytical grade. PE and
ACh were made up as fresh base solutions in physio-
logical salt solution.Animals and experimental design
Eighteen week old male Zucker fa/fa rats were obtained
from Charles River Laboratories (USA) and housed at an
ambient temperature of 22 ± 2°C. Animals were main-
tained on a 12-h day/night cycle with ad libitum access to
standard lab diet (National Institute of Nutrition, Hydera-
bad, India). The Institutional Animals Ethical Committee
Guidelines approved the methods and procedures de-
scribed in the present report. Animals were divided into 6
different groups (n = 7), control vehicle (0.25% Tween 80),
S-Amlodipine (1 mg/kg), Pioglitazone (6 mg/kg), Raga-
glitazar (1 mg/kg), S-Amlodipine (1 mg/kg) + Pioglitazone
(6 mg/kg), S-Amlodipine (1 mg/kg) + Ragaglitazar (1 mg/
kg) by oral gavage once-daily for 14 days.Blood pressure measurement
BP was measured in conscious state using tail-cuff method
(NIBP-4 Columbus instruments, Ohio, USA) after pre-
warming the tail for 15 min at 30°C. To ensure the repro-
ducibility, 10 measurements were made and the mean of
the measurements calculated at day 0 and day 14. The ani-
mals were acclimatized for 15 min. before the experiment
on the experimental day. During BP measurement, the ani-
mals were calm and tail was motionless. The time constant
was set to 120 seconds.Body weight and food intake
Body weight and feed consumption were recoded weekly
to monitor any changes. The amount of feed consump-
tion (in g) over the one week period was recorded for
each treatment group.
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profile, creatinine, and electrolytes
Animals were kept for overnight fasting and blood
was collected by retro-orbital puncture using local
anesthesia. Serum was separated immediately and levels of
glucose, triglyceride (TG), total cholesterol (TC) and
creatinine were analyzed by a Liasys, biochemical
analyzer (AMS, Italy).
Oral Glucose Tolerance Test (OGTT)
A glucose load of 5 g/kg/3 ml was given orally to over-
night fasted (16–18 h) animals and blood was collected
from retrorbital sinus at the subsequent interval of 0,
30, 60 and 120 min. The serum was separated imme-
diately and the samples were analyzed for glucose using a
commercial kit (Pointe scientific, USA) based on the
GOD-POD principle using Spectramax 190 Microplate
Spectrophotometer.
Aortic ring study for the assessment of vascular reactivity
Thoracic aortas were isolated and placed in cold physio-
logical salt solution and cut into 4 mm cylindrical segment
after cleaning the connective tissue. Blood vessels were
mounted in a 20-ml jacketed organ bath (Expermetria
Ltd., Hungary) containing physiological salt solution.
The lumen of each vessel was cannulated with wire hooks;
one end of hook was fastened to stationary glass rod and
the other to an isometric force transducer (Experimetria
Ltd., Hungary) interfaced to computerized data acquisition
program (Acqnowledge v 3.5.7, Biopac Systems, USA).
Physiological salt solution was maintained at 37°C
and aerated with 95% O2 – 5% CO2 throughout the
experiment. Aortic rings were placed under resting
tension (1.5 g) and equilibrated for ~60 min with was-
hing. A cumulative dose response of PE (10 nmol/l –
10 μmol/l) in endothelium intact tissues was recorded
followed by a cumulative dose response to ACh
(30 nmol/l-30 μmol/l) in PE precontracted aorta. Iso-
metric tension was measured as grams of force and
then normalized to maximal contraction to PE. Vaso-
constriction in response to PE was expressed as a per-
centage of the maximal tension generated in response
to 10 μM PE. Relaxation in response to each concentra-
tion of ACh was expressed as the percentage reduction
from the maximal tension generated in response to PE
(1 μM) alone.
Statistical analysis
All data are presented as means ± standard error mean
[SEM]. Unless stated, statistical analyses were done by
one-way ANOVA followed by Dunnet’s significant differ-
ence test for multiple comparisons using Graph Pad
Prism software 4.0. Differences were considered statisti-
cally significant when p < 0.05.Results
Effect on body weight and food intake
Individual treatment with Pioglitazone and Ragaglitazar
showed significant increase in body weight compared to
vehicle group. S-Amlodipine alone or in combination
with Pioglitazone showed less gain in body weight com-
pared to that of individual treatment. The decrease in
body weight was partially correlated with reduction in
food intake (Figure 1a and b).
Effect on serum glucose, lipid profile and creatinine
Serum glucose was reduced significantly with S-Amlodipine,
Pioglitazone and their combination (Table 1). Pioglitazone,
Ragaglitazar and their combinations with S-Amlodipine
showed significant reduction in serum TG levels. S-
Amlodipine alone showed a non-significant trend to-
wards reduction in TG levels. There was no change in
TC levels with any of the treatment (Table 1). Serum
creatinine levels were not significantly different be-
tween the treatments (Table 1).
Effect on oral glucose tolerance
All the treatments including both combinations showed
improvement in glucose tolerance. We found significant
reduction in area under curve [21] with all the treatments
except S-Amlodipine when compared with vehicle group,
but this reduction was not synergistic in action on glucose
tolerance test (Figure 2a and b). All the treatments in-
cluding S-Amlodipine alone inhibited the rise in first
phase insulin at 30 min post glucose load. At 2 h post
glucose load, vehicle treated animals still had higher glu-
cose levels whereas Pioglitazone, Ragaglitazar and their re-
spective combination with S-Amlodipine brought the
glucose levels closer to baseline.
Effect on systolic blood pressure (SBP)
We found significant reduction in SBP with S-Amlodipine
alone or in combinations of S-Amlodipine with both
Ragaglitazar and Pioglitazone. The overall reduction in
SBP was not synergistic with combinations. It could be
possible that the small reduction with Pioglitazone and
Ragaglitazar was due to overall improvement in lipid
and diabetic parameters. S-Amlodipine itself reduced
BP up to a level where Pioglitazone and Ragaglitazar
cannot advantage further at least for BP reduction
(Figure 3).
Effect on smooth muscle relaxation
PE induced contraction was not altered with any of the
treatments (data not shown). ACh induced relaxation was
increased with all the treatment groups but it was more
prominent with combination therapy. S-Amlodipine, Pio-
glitazone and Ragaglitazar have showed 30-40% vasorela-
xation but it was 50–60% with the combination treatments
Figure 1 Effect of treatments on body weight and feed intake. Effect of combination of S-Amlodipine with Ragaglitazar and Pioglitazone on
body weight (A) and food intake (B) after 14 days of treatment in fa/fa rats. Data are shown as means ± S.E.M. n = 7 per group. *Significantly
different from the control (*p < 0.05, **p < 0.01).
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thelial relaxation with both of the combinations, although
it was higher with the S-Amlodipine and Pioglitazone
combination (Figure 4). The reduction in BP with combin-
ation therapy could be attributed to the increased aortic re-
laxation, as both BP reduction and aortic relaxation were
greater with the combination therapy.
Discussion
The major findings from this work are (1) S-Amlodipine
cause reduction in BP, blood glucose and triglyceride levels,
improves insulin sensitivity and induces less gain in body
weight; (2) S-Amlodipine combined with Pioglitazone leads
to significant decrease in serum glucose levels, induces less
gain in body weight with simultaneous improvement in
smooth muscle relaxation; (3) S-Amlodipine combined
with Ragaglitazar shows further improvement in TG
reduction; and (4) combination treatments has no syn-
ergistic impact on BP reduction and insulin sensitivity
in Zucker fa/fa rats.
Metabolic syndrome and type 2 DM, characterized by
obesity, insulin resistance, and dyslipidemia, have reached
an epidemic proportion in developed societies. BloodTable 1 Effect of combination of S-Amlodipine with Ragaglita
Zucker fa/fa rats
Glucose (mg/dl) TC (m
Control 115.18 ± 6.64 139.08
S-Amlodipine 89.71 ± 2.72* 134.94
Pioglitazone 90.60 ± 2.11* 146.50
Ragaglitazar 106.45 ± 1.55 133.58
S-Amlo + Pio 81.76 ± 4.24*$ 131.97
S-Amlo + Raga 103.01 ± 7.48 148.34
Data are shown as means ± S.E.M. n = 7 per group. *significantly different from the
Amlo, Amlodipine; Pio, Pioglitazone; Raga, Ragaglitazar.glucose levels can be controlled pharmacologically to
prevent the majority of complications associated with
diabetes; however the current treatment regime does
not adequately normalize the blood glucose level in
type 2 DM patients [2]. TZDs improve insulin sensitiv-
ity; decrease circulating insulin levels and lower fasting
blood glucose in diabetic individuals. These changes
are associated with reversal of many of the com-
ponents of the insulin resistance syndrome, including
lowered triglycerides, increased high-density lipoprotein
(HDL), decreased small dense low-density lipoprotein
(LDL), reduced circulating plasminogen activator inhibitor-
1 levels, and decreased BP. These observations suggest
that reversal of the insulin resistance syndrome is asso-
ciated with an improvement in the cardiovascular risk
factors associated with insulin resistance [22]. Both
hypertension and type 2 DM are multifaceted dynamic
expressions of pathophysiological disequilibrium that
are closely related by a number of common factors.
The present study was conducted to evaluate com-
bination therapy of PPAR agonists and CCB, S-Amlodipine
as a possible treatment for metabolic syndrome and type
2 DM.zar and Pioglitazone on biochemical parameters in
g/dl) TG (mg/dl) Creatinine
± 14.55 362.56 ± 47.53 0.88 ± 0.08
± 12.89 267.75 ± 17.15 0.78 ± 0.12
± 4.10 230.64 ± 18.81** 0.76 ± 0.04
± 2.59 173.21 ± 15.70** 0.77 ± 0.08
± 10.03 211.14 ± 23.78** 0.80 ± 0.05
± 14.47 252.34 ± 27.86* 0.79 ± 0.04
control (*p < 0.05, **p < 0.01); ($p < 0.05; one-tailed ‘t’ test; Pio vs. Amlo + Pio).
Figure 2 Impact of treatments in oral glucose tolerance test (OGTT). Impact of combination of S-Amlodipine with Ragaglitazar and Pioglitazone
on glucose tolerance after 14 days of treatment in fa/fa rat. A. Glucose levels at different time points. B. Area under the curve (0–120 min) of OGTT.
Data are shown as means ± S.E.M. n = 7 per group. *Significantly different from the control (*p < 0.05, **p < 0.01).
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zone and Ragaglitazar showed significant reduction in
SBP in Zucker fa/fa rats. Combinations did not show
any synergistic effect on BP reduction, as this could be
the maximum or saturation effect of S-Amlodipine
alone. S-Amlodipine lowers both systolic and diastolic
pressure by direct vasodilatation through blocking cal-
cium channels and increases the heart rate by reflex
tachycardia [19]. Individual treatments with Ragaglitazar
and Pioglitazone showed a trend towards reducing BP, but
it was not statistically significant. PPAR-gamma agonists ac-
tivate renal sodium and water reabsorptive pathways, and
lowers BP in normal rats [23]. Recent studies demonstrated
reduction in BP with Pioglitazone or Ragaglitazar treat-
ment, which was mediated through vasodilatation by in-
creasing the nitric oxide (NO) release [13,16]. The present
study demonstrated increased ACh induced relaxation in
aortic rings of Zucker fa/fa rats treated for 14 days with
combination treatment, which shows a better improvement
in endothelial function with the combination therapy com-
pared to individual treatments. The improved endothelialFigure 3 Effect of treatments on systolic blood pressure (SBP).
Effect of combination of S-Amlodipine with Ragaglitazar and Pioglitazone
on SBP after 14 days of treatment in fa/fa rats. Data are shown as
means ± S.E.M. n = 7 per group. *Significantly different from the
control (*p < 0.05).function could be one of the mechanisms for changes in
BP. Recent studies have also identified PI3K-Akt path-
way and hypoxia inducible factor −1 alpha and genetic
basis other than nitric oxide as possible mechanisms for
PPAR induced smooth muscle relaxation and improve-
ment in endothelial dysfunction [24,25].
Weight gain associated with increased food intake is a
major side effect of Pioglitazone treatment in both ani-
mal models and humans. PPAR-gamma increases feed-
ing by reducing leptin levels, a hormone present in the
hypothalamus that regulates satiety center [6]. Increase
in body mass was partially due to increased feeding and
perhaps reabsorption of sodium ions in collecting ducts,
which could cause peripheral edema [1]. PPAR agonists
(Pioglitazone and Ragaglitazar) showed significant weight
gain, associated with increased food intake as previously
reported [6]. Interestingly, S-Amlodipine showed lesser
gain in body weight with reduced feed intake compared to
vehicle group as supported by others in diabetic rats [26].Figure 4 Effect of treatments on ACh induced aorta relaxation.
Effect of combination of S-Amlodipine with Ragaglitazar and Pioglitazone
on ACh induced relaxation on aorta of 14 days treated fa/fa rats. Data
are shown as means ± S.E.M. *Significantly different from the control
(*p < 0.05; #, p < 0.05, Pioglitazone and Amlodipine + Pioglitazone).
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showed lesser gain in body weight compared to the
animals receiving Pioglitazone alone. This reduction in
body weight was well correlated with reduction in food in-
take. The results suggest that combination treatment may
have advantage in controlling weight gain in these
animals.
Serum glucose levels were reduced significantly with
S-Amlodipine and Pioglitazone individually and in
combination. The decrease in blood glucose levels by
S-Amlodipine could be due to the increase in insulin sen-
sitivity as seen in OGTT, which in turn might be related to
the decrease in cytosolic Ca2+ concentration [19,27]. More-
over, S-Amlodipine showed significantly smaller increase
in peak serum glucose levels in OGTT after oral glucose
load, which could be due to increased 1st phase insulin
secretion by S-Amlodipine or other possible mecha-
nisms such as alteration in the beta-adrenergic activity
that in turn influences the insulin release [28]. Both Pio-
glitazone and Ragaglitazar caused a reduction in serum
glucose levels in various animal species by acting as in-
sulin sensitizer [29]. The results of the present study
demonstrated significant reduction in glucose levels
with S-Amlodipine and Pioglitazone in combination.
This is correlated with the increase in insulin sensitivity
as the total area under the curve [21] in OGTT was re-
duced significantly and further reduction in glucose
levels reaching to normal after 2 hour of glucose load
with the combination treatment.
PPAR-alpha agonists are effective in reducing triglycer-
ide (TG) and LDL levels with elevated HDL modulating
various genes like lipoprotein lipase, apolipoprotein C-
III, human apolipoprotein A-I and A-II [30]. A previous
study demonstrated reduced levels of TG and free fatty
acid (FFA) in normal and fa/fa rats induced by Pioglitazone
[31]. The results of the present study suggest significant re-
duction in TG levels with Ragaglitazar treatment due to
PPAR-alpha fraction, which was supported by previous re-
ports [8]. S-Amlodipine showed a partial non-significant
reduction in TG levels as supported by previous studies
[19,26]. The authors suggested that the decrease in TG is
due to the inhibition of intestinal chylomicron secretion
and the enhancement of hepatic uptake of very low-
density lipoprotein (VLDL) [21]. Both the combinations
have demonstrated reduction in TG levels up to the same
extent as individual treatments.
Jian et al. found that plasma creatinine levels were not
significantly different, though creatinine clearance was
significantly reduced by Rosiglitazone treatment, possibly
indicating some fall in glomerular filtration rate. However,
the urinary K+ to Na+ ratio was increased by Rosiglitazone
treatment, indicating selective Na+ reabsorption in the kid-
ney relative to K+ [23]. The present study demonstrated in-
creased Na+ excretion, and improved renal function asindicated by reduction in serum creatinine levels with indi-
vidual treatments. This renal improvement accompanied
with increased Na+ excretion may be one of the factors re-
sponsible for reduction in BP in diabetic rats [19,32]. It is
well known that the Zucker fa/fa rats have abnormal renal
function. It was reported that Pioglitazone and Troglitazone
prevent glomerular dysfunction in diabetic rats by inhib-
ition of the DAG-PKC-ERK pathway with improved renal
function [33]. This improvement in renal function could be
very useful in diabetes-associated complications.
Conclusions
In conclusion, our results suggest that a calcium channel
blockers such as S-Amlodipine combined with PPAR ago-
nists, Pioglitazone or Ragaglitazar, could improve certain
metabolic and cardiovascular risk factors in patients suf-
fering from metabolic syndrome but further studies are
warranted to validate the conclusions.
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